HCW Biologics reports positive early alopecia data
Clinical-stage biopharmaceutical firm HCW Biologics (NASDAQ:HCWB) reported positive preliminary human data from its Phase 1 trial of HCW9302, revealing that all three mild alopecia areata patients in the 3 μg/kg cohort achieved a 25% or greater reduction in SALT scores.





-640x360.webp&w=3840&q=75)




